KEAP1-NRF2 Inhibitors via Localized Binding and Upstream Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds and methods for inhibiting Kelch-like ECH-associated protein 1 (KEAP1) face challenges in target specificity, pharmacodynamic properties, and safety, necessitating the development of new compounds that can effectively inhibit KEAP1 for treating related diseases.
Innovation Solution
The development of specific compounds, such as those described in Formulas (I), (II), and (III), which can inhibit KEAP1 by disrupting its interaction with Nuclear factor erythroid 2-related factor 2 (NRF2), formulated into pharmaceutical compositions for administration to treat diseases associated with the KEAP1-NRF2 axis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing KEAP1 inhibitors are developed and used, then KEAP1 inhibition activity is achieved, but target specificity and safety are compromised
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (Formula I) that target particular regions of the KEAP1 protein. The compounds contain specific functional groups (R1-R7 substituents) that interact with localized binding sites on KEAP1, enabling selective inhibition of the KEAP1-NRF2 interaction while minimizing off-target effects. This localized targeting approach improves both inhibition activity and safety by focusing the pharmacological effect on the desired molecular interaction.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the inhibitor molecules (such as substituent types, molecular weight, lipophilicity) to optimize the balance between KEAP1 inhibition potency and target specificity. By adjusting these chemical parameters within Formula (I), the invention achieves compounds that maintain strong inhibition activity while reducing harmful off-target effects, thus resolving the contradiction between reliability and safety.
2Reliability
If KEAP1 inhibition is enhanced for therapeutic effect, then efficacy against diseases is improved, but pharmacodynamic properties and safety are worsened
Solution Approach 1:
The patent uses the KEAP1-NRF2 interaction as an intermediary target to achieve therapeutic effects indirectly. Rather than directly targeting downstream effectors or multiple pathways, the compounds of Formula (I) specifically modulate the KEAP1-NRF2 protein-protein interaction, which serves as a central regulatory node. This intermediary approach allows for enhanced therapeutic efficacy through NRF2 activation while maintaining better pharmacodynamic properties and safety compared to broader mechanism approaches.
Solution Approach 2:
The patent applies inversion by targeting the inhibitor binding to KEAP1 in a manner that indirectly activates NRF2 rather than directly activating NRF2 or its downstream targets. By inverting the traditional approach of directly targeting the transcription factor, the invention achieves therapeutic benefits through upstream modulation of the KEAP1-NRF2 axis, improving the therapeutic index by avoiding direct interference with complex transcriptional networks.
Data Source
AI summary
Described herein are compounds, compositions and methods useful for inhibiting Kelch-like ECH-associated protein 1 (KEAP1). The compounds, compositions and methods described herein are useful for treating diseases, disorders or conditions associated with KEAP1.